Sunstone
← All Articles
valerian rootpassionflowersleepanxietyherbal medicineGABAinsomnianatural health

Valerian Root and Passionflower: Evidence-Based Herbal Sleep Support

7 January 2026 · 12 min read

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented here is not intended to diagnose, treat, cure, or prevent any condition. Always consult a qualified healthcare professional before beginning any supplementation, particularly if you are pregnant, breastfeeding, taking medications, or managing a diagnosed sleep disorder.

Sleep is among the most studied targets in integrative medicine, and two botanicals consistently appear in the clinical literature: Valeriana officinalis (valerian root) and Passiflora incarnata (passionflower). Unlike many herbal remedies that rely heavily on traditional use with minimal mechanistic grounding, these two plants have genuine pharmacological rationale and a reasonably sized body of controlled trial evidence behind them. Neither is a silver bullet, and the research has its limitations — but both offer a low-risk, low-dependence option for people dealing with mild-to-moderate insomnia or sleep-onset difficulty.

This article examines what is actually known about each herb: the active constituents, the proposed mechanisms, the clinical trial results with appropriate caveats, optimal dosing forms and timing, how they perform together, and how they compare to pharmaceutical sleep aids.

Valerian Root: Mechanisms and Constituents

Valeriana officinalis is a perennial herb native to Europe and parts of Asia, with a history of use stretching back to ancient Greece and Rome. The dried root and rhizome are the medicinally relevant parts.

Key active constituents include:

  • Valerenic acid and acetylvalerenic acid — sesquiterpene acids considered the primary bioactive markers; standardised extracts are typically expressed as a percentage of these compounds
  • Isovaleric acid — a volatile fatty acid that contributes the herb's characteristic pungent odour and may have mild sedative properties
  • GABA (gamma-aminobutyric acid) — free GABA has been detected in valerian root extracts, though oral GABA absorption across the blood-brain barrier remains a subject of debate
  • Lignans — including pinoresinol and hydroxypinoresinol, which may interact with adenosine receptors
  • Iridoid valepotriates — unstable compounds (valtrate, isovaltrate) present in fresh root material but largely degraded during drying and storage; their contribution to dried extract activity is considered minor

Mechanism of action

The most substantiated mechanism involves valerenic acid acting as a partial positive allosteric modulator of GABA-A receptors — the same receptor family targeted by benzodiazepines and Z-drugs, but via a different binding site and with considerably weaker and more selective activity. A key in vitro finding is that valerenic acid inhibits the enzyme GABA transaminase (GABA-T), which is responsible for breaking down GABA in the synapse. By slowing GABA catabolism, valerenic acid may elevate synaptic GABA concentrations, prolonging inhibitory signalling in sleep-relevant brain regions. This dual action — receptor modulation plus reduced GABA breakdown — provides a plausible mechanistic framework for its anxiolytic and sleep-promoting effects.

Beyond the GABAergic pathway, valerian lignans appear to interact with adenosine A1 receptors. Adenosine is an endogenous sleep-promoting molecule that accumulates during wakefulness and is the target inhibited by caffeine. This adenosine receptor activity could independently contribute to sedation, separate from GABA modulation.

Valerian: Clinical Evidence

The clinical evidence for valerian spans more than four decades and includes some of the earliest rigorous studies on herbal sleep aids.

Leathwood et al. (1982, Pharmacology Biochemistry and Behavior) conducted one of the foundational randomised controlled trials. Participants received either 450 mg of aqueous valerian extract, 900 mg, or placebo in a crossover design. Both active doses produced statistically significant improvements in subjective sleep latency (time to fall asleep) and overall sleep quality ratings. Notably, the 450 mg dose performed comparably to the 900 mg dose on most measures, and morning-after sedation was not significantly increased at either dose — an early signal of the herb's favourable tolerability profile.

Donath et al. (2000, Pharmacology Biochemistry and Behavior) applied a more rigorous objective methodology, using polysomnography (PSG) — the gold standard for sleep architecture measurement — to assess valerian's effects over a two-week treatment period. Results showed a statistically significant increase in the percentage of time spent in slow-wave (deep) sleep compared to placebo. This is a clinically meaningful finding because slow-wave sleep is the most restorative stage and is often selectively impaired in insomnia patients and older adults. The PSG findings gave objective weight to what had previously been largely subjective self-report data.

Bent et al. (2006) published what is effectively the most comprehensive systematic review of valerian for sleep, evaluating 16 randomised controlled trials. The review's conclusions are instructive: the majority of trials reported positive effects on sleep quality and/or latency, but the overall evidence was rated as heterogeneous in methodology, outcome measures, extract preparation, and duration. Some trials used aqueous extracts, others ethanolic; doses ranged widely; study populations varied. The honest summary is that the direction of evidence is generally positive, but the quality is too inconsistent to make definitive efficacy claims. Valerian appears to be better than placebo for subjective sleep quality in most trials, but the magnitude of effect is modest.

What the evidence supports: Valerian is a reasonable first-line herbal option for people with mild sleep onset difficulty and subjective poor sleep quality. It is unlikely to match the acute efficacy of pharmaceutical sedatives, but its tolerability and low dependence risk make it worth considering for long-term mild insomnia management.

Valerian: Forms and Optimal Use

Extract type: Aqueous (water-based) extracts and hydroethanolic extracts are both used commercially. The evidence base includes both, with no clear superiority established. Aqueous extracts preserve more of the polar GABA-related compounds; ethanolic extracts may better capture valerenic acid and sesquiterpenes. Most commercially standardised products use a hydroethanolic extraction process.

Standardisation: Look for extracts standardised to 0.8% valerenic acid. This is the most commonly used benchmark in the research literature and allows for reasonable dose consistency between products.

Dosage: The most studied range is 300–600 mg of standardised extract taken 30–60 minutes before sleep. The Leathwood trial used 450–900 mg; most subsequent trials cluster around 300–600 mg. Starting at the lower end (300 mg) allows tolerance assessment before escalating.

Cumulative effect: This is an important practical point often overlooked. Valerian is not a fast-acting sedative in the way that a benzodiazepine is. Clinical observations and trial data suggest it may take 2–4 weeks of consistent nightly use before the full benefit is apparent. Patients expecting immediate effects may abandon the herb prematurely. Setting appropriate expectations — that this is a slow-building intervention rather than an acute sleep aid — is essential for compliance and realistic outcome assessment.

Passionflower: Mechanisms and Constituents

Passiflora incarnata is native to the southeastern United States and has been used medicinally by indigenous peoples of North America for centuries, primarily as a calming herb. Modern interest centres on its flavonoid-rich profile and anxiolytic properties.

Key active constituents include:

  • Chrysin (5,7-dihydroxyflavone) — the most pharmacologically studied flavonoid in passionflower; primary candidate for its anxiolytic and sleep-modulating effects
  • Vitexin, isovitexin, and orientin — C-glycosylflavones with documented antioxidant activity and emerging evidence for CNS modulation
  • Maltol — a pyranone compound that may contribute to sedative effects
  • Harmane alkaloids — present in small amounts; these beta-carbolines are MAO-inhibitors at high concentrations, but their contribution at typical supplemental doses is debated

Mechanism of action

The primary proposed mechanism for passionflower's anxiolytic activity involves chrysin acting as a partial agonist at the benzodiazepine site of the GABA-A receptor. A pivotal binding study by Wolfman et al. (1994) demonstrated that chrysin bound to benzodiazepine receptors in rat brain tissue with meaningful affinity and produced anxiolytic effects in animal models comparable in direction — though not magnitude — to diazepam. Crucially, chrysin's partial agonism is significantly weaker than benzodiazepine full agonism, which is consistent with its much lower dependence risk and milder clinical effect. The implication is that passionflower engages the same receptor system as benzodiazepines but with a fraction of the efficacy and without the full occupancy that drives tolerance and withdrawal.

Passionflower: Clinical Evidence

Passionflower's clinical evidence is smaller in volume than valerian's but includes some well-designed trials.

Movafegh et al. (2008, Anesthesia & Analgesia) conducted an RCT using a preoperative anxiety model — a reliable, high-validity paradigm for testing anxiolytic compounds because the anxiety is acute, measurable, and consistent across participants. Patients received either 500 mg of oral passionflower extract or placebo 90 minutes before surgery. The passionflower group showed significantly lower preoperative anxiety scores without significant differences in sedation, psychomotor performance, or haemodynamic parameters. The separation of anxiolysis from sedation is a key clinically favourable characteristic.

Ngan and Conduit (2011, Phytotherapy Research) conducted a placebo-controlled crossover trial specifically targeting sleep. Participants consumed a passionflower herbal tea or a control tea for one week, with sleep quality recorded via standardised sleep diary. The passionflower group reported statistically significant improvements in overall sleep quality scores. While sleep diary data is subjective, the crossover design and within-subject comparisons strengthen the findings.

Aslanargun et al. (2012, European Journal of Anaesthesiology) replicated and extended the Movafegh model, again demonstrating significant reductions in preoperative anxiety scores with passionflower extract compared to placebo, without inducing excessive sedation. Taken together, the anaesthetic preoperative studies provide consistent evidence for anxiolytic activity in a controlled, reproducible setting.

Combination Products: Valerian, Passionflower, and Lemon Balm

In traditional European herbal medicine, valerian is rarely used alone for sleep — it is most commonly combined with lemon balm (Melissa officinalis) and/or passionflower. This combination has synergistic logic: valerian primarily modulates GABA-A receptors and reduces GABA breakdown; passionflower provides additional benzodiazepine-site partial agonism; and lemon balm inhibits GABA transaminase via its rosmarinic acid content, complementing valerian's enzyme-inhibiting activity.

Dimpfel et al. (2020, Nutrients) conducted a placebo-controlled trial using polysomnography to assess the combination of valerian, passionflower, and lemon balm in adults with sleep disturbances. The combination showed statistically significant improvements in total sleep time, sleep efficiency, and the proportion of time in deep sleep compared to placebo — replicating and extending the single-herb polysomnographic findings while providing evidence that the combination performs better than individual herbs at equivalent doses.

This multi-herb approach is now standard in higher-quality commercial sleep formulations. For those interested in the broader landscape of botanical synergies, the adaptogenic herb comparison framework provides useful context on how different herb classes are categorised and combined.

How Valerian and Passionflower Compare to Pharmaceutical Sleep Aids

Understanding the pharmacological landscape helps contextualise where herbal sleep aids genuinely fit.

Melatonin is not a sedative — it is a circadian signal. It tells the brain's clock what time it is, which can help with sleep onset when the circadian rhythm is misaligned (jet lag, shift work, delayed sleep phase). It does not have significant sedative properties and does not address the GABAergic pathway. Valerian and passionflower are genuinely complementary to melatonin rather than competitive with it.

Benzodiazepines (temazepam, diazepam, nitrazepam) are full positive allosteric modulators at GABA-A benzodiazepine receptors. Full agonism drives fast tolerance, physical dependence, next-day sedation, cognitive impairment, and rebound insomnia on cessation. Valerian and passionflower engage the same receptor family via partial agonism at distinct or overlapping sites with far weaker receptor occupancy — which is precisely why their dependence risk is negligible and their side-effect profile is mild.

Z-drugs (zolpidem, eszopiclone, zaleplon) bind the same benzodiazepine site of the GABA-A receptor and have essentially the same dependence liability as benzodiazepines despite early marketing claims to the contrary. They are fast-acting and reliably effective acutely but carry the same tolerance and withdrawal risks with chronic use.

For mild-to-moderate insomnia — particularly sleep-onset difficulty in otherwise healthy adults — valerian and passionflower represent the most pharmacologically rational low-dependence herbal alternatives. They will not substitute for pharmaceuticals in severe insomnia, but they occupy a useful therapeutic niche between lifestyle interventions (sleep hygiene, cognitive behavioural therapy for insomnia) and prescription sedatives. This evidence-based positioning is part of what informs the botanical actives research catalogue, which applies similar scrutiny to botanical actives across multiple categories.

Safety Profile and Contraindications

Valerian

  • Generally well tolerated in clinical trials at doses up to 600 mg for periods of up to 28 days
  • The most commonly reported adverse event is paradoxical mild stimulation in a minority of users — particularly at initial doses — rather than sedation
  • At higher doses or in sensitive individuals, next-morning drowsiness may occur; this typically resolves with dose reduction
  • Rare case reports of hepatotoxicity have been attributed to valerian-containing products, but toxicological review has generally concluded these cases likely involved product adulteration with unrelated hepatotoxic herbs rather than valerian itself
  • Contraindicated with CNS depressants (alcohol, benzodiazepines, opioids, anaesthetic agents) due to additive sedative effects
  • Avoid during pregnancy and breastfeeding due to insufficient safety data
  • Theoretically may interact with CYP3A4-metabolised medications due to inhibitory activity observed in vitro; clinical significance at typical doses is uncertain

Passionflower

  • Considered safe for short-to-medium-term use based on clinical trial data and traditional use
  • Main adverse effect at higher doses is mild sedation; this is dose-dependent and generally manageable
  • The same CNS depressant contraindication applies; additive sedation with other sedating agents
  • Contraindicated in pregnancy due to the presence of harmane alkaloids with potential uterine stimulant effects in animal models
  • Avoid in individuals taking MAO-inhibitor medications given the beta-carboline alkaloid content, even though concentrations at standard doses are low
  • Limited data on safety beyond 8 weeks of continuous use

Connecting the Evidence

The sleep-supporting botanical literature is considerably larger than most clinicians appreciate. Both valerian and passionflower have genuine mechanistic grounding in GABAergic pharmacology, reasonable clinical evidence for mild insomnia and anxiety, favourable tolerability, and no dependence liability at standard doses. The research on reishi mushroom's immune and adaptogenic properties and astragalus root's longevity-associated mechanisms reflects a similar pattern: traditional use, emerging mechanistic science, and a growing controlled trial base that — while imperfect — consistently points in a positive direction.

The honest evidence-based position for valerian and passionflower is this: they are not as acutely effective as pharmaceutical sedatives, the research quality varies, and individual response differs. But for mild sleep difficulty, particularly sleep-onset problems and sleep-related anxiety, they offer a biologically plausible, generally safe, and non-habit-forming option that is backed by more clinical evidence than most people realise.

Always consult a healthcare professional before adding any supplement to your routine, especially if you are taking medications or have a diagnosed health condition.